Structured evidence table for Lutein Supplementation Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Lutein Supplementation Cognition Randomized Trial | Results Compared to the placebo, lutein and zeaxanthin supplementation was associated with greater improvements in visual episodic memory ( p = 0.005) and visual learning ( p = 0.001). | 2 | Lopresti AL (2022) | The Effects of Lutein and Zeaxanthin Supplementation on Cognitive Function in Adults With Self-Reported Mild Cognitive Complaints: A Randomized, Double-Blind, Placebo-Controlled Study. |
| Lutein Supplementation Cognition Randomized Trial | Conclusion The results from this trial suggest that 6-months of supplementation with lutein and zeaxanthin may improve visual memory and learning in community-dwelling adults with self-reported cognitive complaints. | 2 | Lopresti AL (2022) | The Effects of Lutein and Zeaxanthin Supplementation on Cognitive Function in Adults With Self-Reported Mild Cognitive Complaints: A Randomized, Double-Blind, Placebo-Controlled Study. |
| Lutein Supplementation Cognition Randomized Trial | Background Lutein and zeaxanthin are fat-soluble, dietary carotenoids with high concentrations in human brain tissue. | 2 | Lopresti AL (2022) | The Effects of Lutein and Zeaxanthin Supplementation on Cognitive Function in Adults With Self-Reported Mild Cognitive Complaints: A Randomized, Double-Blind, Placebo-Controlled Study. |
| Lutein Supplementation Cognition Randomized Trial | There have been a number studies confirming an association between lutein and zeaxanthin and cognitive function. | 2 | Lopresti AL (2022) | The Effects of Lutein and Zeaxanthin Supplementation on Cognitive Function in Adults With Self-Reported Mild Cognitive Complaints: A Randomized, Double-Blind, Placebo-Controlled Study. |
| Lutein Supplementation Cognition Randomized Trial | While the precise aetiology of AD remains unclear, ongoing research has yielded increasing evidence that disturbance of the biological processes associated with healthy brain ageing contribute to AD. | 3 | Ward Keanie (2025) | Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease |
| Lutein Supplementation Cognition Randomized Trial | Age is the most prominent risk factor for AD, and it has been suggested that those aged 65 and over have a 1–2% risk, while those aged 85 and over have an 18–38% risk [,]. | 3 | Ward Keanie (2025) | Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease |
| Lutein Supplementation Cognition Randomized Trial | It is crucial to differentiate pathological cognitive decline, observed in AD, from the cognitive changes associated with physiological ageing []. | 3 | Ward Keanie (2025) | Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease |
| Lutein Supplementation Cognition Randomized Trial | 1 2 3 4 5 6 7 Figure 1 8 9 10 7 11 12 13 14 15 Cognitive decline, whether age-related or indicative of neurodegenerative disorders such as dementia, is an escalating global health concern. | 3 | Ward Keanie (2025) | Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease |
Source documents